15 Biotechnology Stocks to Buy Now

Advertisement

The grades of 15 biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Epizyme, Inc. (EPZM) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) gets a higher grade this week, advancing from a C last week to a B. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

The rating of Acorda Therapeutics, Inc. (ACOR) moves up this week, rising from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Northwest Biotherapeutics, Inc. (NWBO) improves from a C to a B rating this week. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

This week, Cellular Biomedicine Group, Inc.’s (CBMG) ratings are up from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of CBMG stock.

This is a strong week for Conatus Pharmaceuticals Inc. (CNAT). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

Ophthotech Corp. (OPHT) improves from a B to an A rating this week. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

MediciNova, Inc. (MNOV) earns an A this week, jumping up from last week’s grade of B. Medicinova acquires, develops, and commercializes small molecule therapeutics. Shares of the stock have been trading at an exceptionally rapid pace, up 392.8% from the week prior. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

BioMarin Pharmaceutical (BMRN) gets a higher grade this week, advancing from a C last week to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

This week, Seattle Genetics, Inc.’s (SGEN) ratings are up from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Esperion Therapeutics, Inc. (ESPR) is seeing ratings go up from a B last week to an A this week. For more information, get Portfolio Grader’s complete analysis of ESPR stock.

BIND Therapeutics, Inc. (BIND) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of BIND stock.

This week, Amgen (AMGN) pushes up from a B to an A rating. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/11/15-biotechnology-stocks-to-buy-now-epzm-stml-pcyc/.

©2024 InvestorPlace Media, LLC